Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

FDA Approvals, Stock Price Updates, New Study Results, Conference Schedules and Partnerships - Research Report on Merck,



 FDA Approvals, Stock Price Updates, New Study Results, Conference Schedules
   and Partnerships - Research Report on Merck, Pharmacyclics, UnitedHealth
                      Group, Medtronic, and AstraZeneca

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, November 29, 2013

NEW YORK, November 29, 2013 /PRNewswire/ --

.

Today, Analysts' Corner announced new research reports highlighting Merck &
Co., Inc. (NYSE: MRK), Pharmacyclics, Inc. (NASDAQ: PCYC), UnitedHealth Group
Inc. (NYSE: UNH), Medtronic, Inc. (NYSE: MDT) and AstraZeneca plc (ADR) (NYSE:
AZN). Today's readers may access these reports free of charge - including full
price targets, industry analysis and analyst ratings - via the links below.

Merck & Co., Inc. Research Report

On November 26, 2013, Merck & Co., Inc. (Merck) announced that the U.S. Food
and Drug Administration (FDA) has approved NOXAFIL (posaconazole) 100 mg
delayed-release tablets. According to the Company, NOXAFIL delayed-release
tablets are a new formulation with a loading dose of 300 mg (three 100 mg
delayed-release tablets) twice daily on the first day, followed by a
once-daily maintenance dose of 300 mg (three 100 mg delayed-release tablets)
starting on the second therapy. The Company also markets NOXAFIL (40 mg/mL)
oral suspension, which is dosed three times daily. Merck informed that NOXAFIL
delayed-release tablets and oral suspension are indicated for the prophylaxis
of invasive Aspergillus and Candida infections in patients, 13 years of age
and older, who are at high risk of developing these infections due to being
severely immunocompromised, such as hematopoietic stem cell transplant (HSCT)
recipients with graft-versus-host disease (GVHD) or those with hematologic
malignancies with prolonged neutropenia (low white blood cell counts) from
chemotherapy. The Full Research Report on Merck & Co., Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/430d_MRK

--

Pharmacyclics, Inc. Research Report

On November 26, 2013, Pharmacyclics Inc.'s (Pharmacyclics) stock declined
0.70%, ending the day at $123.83. Over the previous three trading sessions,
shares of Pharmacyclics declined 1.79% compared to the Nasdaq Composite which
gained 1.22% during the same period. The Full Research Report on
Pharmacyclics, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/df74_PCYC

--

UnitedHealth Group Inc. Research Report

On November 25, 2013, UnitedHealth Group Inc. (UnitedHealth) announced the
results of a new study "Scope-Of-Practice Laws For Nurse Practitioners Limit
Cost Savings that can be Achieved in Retail Clinics," co-led by the Company's
Center for Nursing advancement. According to UnitedHealth, the report shows
that nurse practitioners (NPs) practicing in retail clinics have the potential
to deliver significant cost savings when treating a range of common
conditions, with the greatest savings occurring in states that allow NPs to
practice independently. The Company added that the research did not show any
erosion in quality, as measured through excess ER visits or hospitalizations
following the use of the retail clinic, meaning cost savings can be realized
without lowering the quality of care. Dawn Bazarko, D.N.P., M.P.H., R.N.,
Senior Vice President of the UnitedHealth Group Center for Nursing Advancement
and Co-Author of the Study, said, "This study helps confirm a new reality in
today's health system: all care providers must be allowed to fully use their
skills and education to meet our nation's increasingly complex health care
needs. As one of the nation's largest employers of nurses, UnitedHealth Group
understands that this is especially important for nurse practitioners, who
will continue to play a vital role in increasing access to affordable,
high-quality care for everyone." The Full Research Report on UnitedHealth
Group Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/73e5_UNH

--

Medtronic, Inc. Research Report

On November 26, 2013, Medtronic, Inc. (Medtronic) announced that it will
participate in the Piper Jaffray Healthcare Conference on December 3, 2013, in
New York. The Company said that the Executive Vice President and President of
Medtronic's Cardiac and Vascular Group, Mike Coyle, will make a presentation
about the Company beginning at 1:30 p.m. ET (12:30 p.m. CT). A live audio
webcast of the presentation will be available on the day of the conference,
and can be accessed by clicking on the Investors link on the Company's
website. The Full Research Report on Medtronic, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/bc94_MDT

--

AstraZeneca plc (ADR) Research Report

On November 19, 2013, AstraZeneca plc's (ADR) (AstraZeneca) announced that it
has selected Herzog & de Meuron to design the Company's new center in the UK.
AstraZeneca said that the site, to be located on the Cambridge Biomedical
Campus (CBC), will be home to one of the three global strategic R&D central
centers and the Company's corporate headquarters, with a workforce of
approximately 2,000. AstraZeneca added that the previously announced £330
million investment in Cambridge will create a working environment that fosters
innovation in one of the world's pre-eminent biosciences hotspots, ultimately
helping AstraZeneca improve pipeline productivity. AstraZeneca expects
approximately 400 employees, primarily scientists involved in research and
development to move to Cambridge in 2014 and will be based across three
temporary sites at the Melbourn Science Park, the Cambridge Science Park, and
Granta Park. The Full Research Report on AstraZeneca plc (ADR) - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/09cc_AZN

----

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement